IP Library Granted Patent US 12,435,357
Granted Patent B2
US 12,435,357 · App. 18/087,147 · Granted Oct 7, 2025

Diagnostic device for detecting a target nucleic acid molecule in a biological sample

Inventors: Roy Rabinowitz (Tel Aviv-Jaffa, IL); Omer Stoller (Ramat Gan, IL)
Assignee: KANSO DIAGNOSTICS LTD.
C12Q1/6816B01L3/502761C12Q1/6844C12Q1/6869B01L2200/026B01L2300/044B01L2300/0681B01L2300/0848B01L2300/0861B01L2400/0622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,357
App. No.
18/087,147
Granted
Oct 7, 2025
Kind
B2
Abstract

Diagnostic devices comprising: an inlet for receiving a solution comprising a biological sample comprising a target nucleic acid molecule; at least one reaction chamber, comprising a nuclease for cleaving a nucleic acid molecule, into a first portion bonded to a marker and a second portion bonded to a bulky molecule; a membrane in liquid connection to the at least one reaction chamber, having porosity sized to filter the first portion from the solution containing the second portion; and an informative chamber configured to receive the filtered first portion, having at least one of, a transparent region showing a visible marker; and a detector for detecting the marker are provided. Methods of using the devices to detect a target nucleic acid molecule in a sample are also provided.

Claims (33)

1. A diagnostic device, comprising:

a body comprising:

an inlet for receiving a solution comprising a biological sample comprising a target nucleic acid molecule;

a plurality of reaction chambers, in liquid connection to the inlet, preloaded with nucleases capable of cleaving a nucleic acid molecule, into a first portion and a second portion;

a membrane placed between said plurality of reaction chambers and an informative chamber;

one or more valves located prior to said membrane,

and wherein said membrane has porosity sized to filter out molecules;

and wherein said informative chamber is configured to receive the filtered first portion, and wherein said informative chamber has at least one of,

a transparent region; and

a detector for detecting the marker.

2. The diagnostic device of claim 1 , wherein the plurality of reaction chambers comprise two chambers:

a first reaction chamber, in liquid connection to the inlet, comprising the bulky molecules; and

a second reaction chamber, in liquid connection to the first reaction chamber, comprising the nuclease.

3. The diagnostic device of claim 2 , wherein the first reaction chamber is preloaded with bulky molecules and said bulky molecules are bonded to the target nucleic acid molecule within the first reaction chamber and the nuclease is preloaded in the second reaction chamber and the target nucleic acid molecule is cleaved in the second reaction chamber.

4. The diagnostic device of claim 3 , wherein said target nucleic acid molecule comprises a capture moiety and said bulky molecules and said second reaction chamber is preloaded with a capturing moiety and wherein said capture moiety and capturing moiety are configured to bind to each other.

5. The diagnostic device of claim 1 , wherein the nuclease is specific to a sequence within the target nucleic acid molecule.

6. The diagnostic device of claim 1 , wherein the plurality of reaction chambers are further preloaded with single stranded DNA/RNA probes, each bonded to a marker and a bulky molecule, and wherein the nuclease cleaves the single stranded DNA probes only in the presence of the target nucleic acid molecule.

7. The diagnostic device of claim 1 , comprising a plurality of parallel reaction chambers, each being in liquid connection to the inlet, wherein each reaction chamber of said plurality comprises a nuclease specific to a different target nucleic acid sequence or configured to cleave preloaded DNA/RNA probes in the presence of a different target nucleic acid molecule.

8. The diagnostic device of claim 1 , comprising a single first reaction chamber, in liquid connection to the inlet, preloaded with bulky molecules; and a plurality of second reaction chambers, in liquid connection to the single first reaction chamber, wherein each reaction chamber of said plurality of second reaction chambers is preloaded with a nuclease specific to a different target nucleic acid sequence or configured to cleave DNA/RNA probes in the presence of a different target nucleic acid molecule.

9. The diagnostic device of claim 1 , wherein said one or more valves are located at an entrance to each reaction chamber.

10. The diagnostic device of claim 1 , further comprising a flat body configured to hold the inlet, the plurality of reaction chambers, the membrane and the informative chamber, wherein the thickness of the flat body is between 1 to 100 mm.

11. The diagnostic device of claim 1 , further comprising:

a container for collecting the solution comprising the biological sample and wherein said membrane is located between said inlet and said plurality of reaction chambers; and an additional membrane, located between said inlet and said container and configured to filter the target nucleic acid molecule from the solution, prior to entering said inlet.

12. The diagnostic device of claim 11 , further comprising a sample provision mechanism that includes one or more pistons, each being located inside a corresponding reaction chamber and configured to introduce a filtered solution containing said target nucleic acid molecule into said plurality of reaction chambers and to extract said solution comprising said first portion from said plurality of reaction chambers back into the inlet.

13. The diagnostic device of claim 1 , further comprising a first chamber formed between a slidable element sliding over the body of the diagnostic device and wherein the inlet being a sample inlet is an entrance in the body.

14. The diagnostic device of claim 13 , wherein the first chamber is preloaded with a polymerase and primers comprising a capture moiety, wherein said primers comprise a sequence capable of hybridizing to said target nucleic acid molecule and wherein said first chamber is preloaded with primers comprising said marker.

15. The diagnostic device of claim 13 , wherein the first chamber is preloaded with magnetic beads comprising a capturing moiety, optionally wherein said magnetic bead is a bulky molecule comprising a magnetic moiety,

and wherein the devices further comprises:

a magnetic bead reservoir for introducing magnetic beads into the first chamber comprising the solution comprising the biological sample, by sliding the slidable element to position the magnetic bead reservoir in fluid contact with said first chamber, optionally wherein said magnetic beads comprise a capturing moiety.

16. The diagnostic device of claim 13 , further comprising:

an electromagnet located in the slidable element located at the same location as the magnetic bead reservoir;

at least one second reaction chamber preloaded with the nuclease located after the first reaction chamber in the body in the sliding direction; and

a piston capable of drawing fluid through said membrane and into said informative chamber.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2022
From: RABINOWITZ, ROY; STOLLER, OMER
To: KANSO DIAGNOSTICS LTD.
Reel/Frame 062186/0502 →
Continuity (1)
Related Publication 20240209418A1 · Jun 27, 2024
References Cited (75)
US 10611827B2 · Aman et al. · 2020 [cited by applicant]
US 11021740B2 · Abudayyeh et al. · 2021 [cited by applicant]
US 11525134B2 · Van Den Boom et al. · 2022 [cited by applicant]
US 11536707B2 · Sullivan et al. · 2022 [cited by applicant]
US 11543353B2 · Qi et al. · 2023 [cited by applicant]
US 11584955B2 · Wang et al. · 2023 [cited by applicant]
US 20060024757A1 · Hussa et al. · 2006 [cited by applicant]
US 20060160243A1 · Tang · 2006 [cited by examiner]
US 20070042505A1 · Israel et al. · 2007 [cited by applicant]
US 20070243137A1 · Hainfeld · 2007 [cited by applicant]
US 20100062415A1 · Schwoebel et al. · 2010 [cited by applicant]
US 20100294811A1 · Akechi · 2010 [cited by examiner]
US 20120071342A1 · Lochhead et al. · 2012 [cited by applicant]
US 20130203627A1 · Moll et al. · 2013 [cited by applicant]
US 20160187333A1 · Moll et al. · 2016 [cited by applicant]
US 20160228874A1 · Lee et al. · 2016 [cited by applicant]
US 20180305773A1 · Abudayyeh et al. · 2018 [cited by applicant]
US 20180356405A1 · Chou · 2018 [cited by applicant]
US 20190321486A1 · Zink et al. · 2019 [cited by applicant]
US 20190346435A1 · Yanik et al. · 2019 [cited by applicant]
US 20200032325A1 · Baughman et al. · 2020 [cited by applicant]
US 20200249228A1 · Jiang et al. · 2020 [cited by applicant]
US 20200263167A1 · Van Den Boom et al. · 2020 [cited by applicant]
US 20200299677A1 · Van Den Boom et al. · 2020 [cited by applicant]
US 20210199651A1 · Zenhausern et al. · 2021 [cited by applicant]
US 20210252150A1 · Crowe, Jr. · 2021 [cited by applicant]
US 20210255172A1 · Beskok et al. · 2021 [cited by applicant]
US 20210292721A1 · Zhang et al. · 2021 [cited by applicant]
US 20210292823A1 · Zhang et al. · 2021 [cited by applicant]
US 20210292824A1 · Zhang et al. · 2021 [cited by applicant]
US 20220042910A1 · Qi et al. · 2022 [cited by applicant]
US 20220044074A1 · Li et al. · 2022 [cited by applicant]
US 20220072120A1 · Kanekiyo et al. · 2022 [cited by applicant]
US 20220099675A1 · Chen et al. · 2022 [cited by applicant]
US 20220106647A1 · Baughman et al. · 2022 [cited by applicant]
US 20220162591A1 · Van Den Boom et al. · 2022 [cited by applicant]
US 20220170071A1 · Brown, III et al. · 2022 [cited by applicant]
US 20220289828A1 · Crowe, Jr. et al. · 2022 [cited by applicant]
US 20220298203A1 · Altschul et al. · 2022 [cited by applicant]
WO 2017218573A1 · 2017 [cited by applicant]
WO 2017219027A1 · 2017 [cited by applicant]
WO 2018064352A1 · 2018 [cited by applicant]
WO 2018107129A1 · 2018 [cited by applicant]
WO 2018170340A1 · 2018 [cited by applicant]
WO 2019010422A1 · 2019 [cited by applicant]
WO 2019018423A1 · 2019 [cited by applicant]
WO 2019051318A1 · 2019 [cited by applicant]
WO 2019089796A1 · 2019 [cited by applicant]
WO 2019089820A1 · 2019 [cited by applicant]
WO 2019104058A1 · 2019 [cited by applicant]
WO 2019126577A2 · 2019 [cited by applicant]
WO 2019126716A1 · 2019 [cited by applicant]
WO 2020006036A1 · 2020 [cited by applicant]
WO 2020006049A1 · 2020 [cited by applicant]
WO 2020006067A1 · 2020 [cited by applicant]
WO 2020028729A1 · 2020 [cited by applicant]
WO 2020142739A1 · 2020 [cited by applicant]
WO 2020142754A2 · 2020 [cited by applicant]
WO 2020186231A2 · 2020 [cited by applicant]
WO 2021046257A1 · 2021 [cited by applicant]
WO 2021163584A1 · 2021 [cited by applicant]
Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, Doudna JA. CRISPR-Cas 12a target binding unleashes indiscriminate single-stranded DNase activity. Science. Apr. 27, 2018;360(6387):436-439. doi: 10.1126/sci… [cited by applicant]
Gao P, Yang H, Rajashankar KR, Huang Z, Patel DJ. Type V CRISPR-Cas Cpf1 endonuclease employs a unique mechanism for crRNA-mediated target DNA recognition. Cell Res. Aug. 2016;26(8):901-13. doi: 10.1038/cr.2016.88. Epub… [cited by applicant]
Ma E, Harrington LB, O'Connell MR, Zhou K, Doudna JA. Single-Stranded DNA Cleavage by Divergent CRISPR-Cas9 Enzymes. Mol Cell. Nov. 5, 2015;60(3):398-407. doi: 10.1016/j.molcel.2015.10.030. PMID: 26545076; PMCID: PMC463… [cited by applicant]
East-Seletsky A, O'Connell MR, Knight SC, Burstein D, Cate JH, Tjian R, Doudna JA. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature. Oct. 13, 2016;538(7624):270-273. doi… [cited by applicant]
Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, Verdine V, Donghia N, Daringer NM, Freije CA, Myhrvold C, Bhattacharyya RP, Livny J, Regev A, Koonin EV, Hung DT, Sabeti PC, Collins JJ, Zhang F. Nu… [cited by applicant]
Singh, D. et al. Real-time observation of DNA target interrogation and product release by the RNA-guided endonuclease CRISPR Cpf1. (2017). bioRxiv 205575; doi: https://doi.org/10.1101/205575. [cited by applicant]
Sternberg SH, Redding S, Jinek M, Greene EC, Doudna Ja. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. Mar. 6, 2014;507(7490):62-7. doi: 10.1038/nature13011. Epub Jan. 29, 2014. PMID: 24476820; PM… [cited by applicant]
Samai P, Pyenson N, Jiang W, Goldberg GW, Hatoum-Aslan A, Marraffini LA. Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity. Cell. May 21, 2015;161(5):1164-1174. doi: 10.1016/j.cell.2015.04.027.… [cited by applicant]
Silva SJRD, Paiva MHS, Guedes DRD, Krokovsky L, Melo FL, Silva Mald, Silva AD, Ayres CFJ, Pena LJ. Development and Validation of Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) for Rapid Detection… [cited by applicant]
Nath P, Kabir A, Khoubafarin Doust S, Kreais ZJ, Ray A. Detection of Bacterial and Viral Pathogens Using Photonic Point-of-Care Devices. Diagnostics (Basel). Oct. 19, 2020;10(10):841. doi: 10.3390/diagnostics10100841. P… [cited by applicant]
Mustafa, M. I., & Makhawi, A. M. (2020). Sherlock and Detectr: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases. Journal of Clinical Microbiology. doi:10.1128/jcm.00745-20. [cited by applicant]
Sharma, A. and Changotra, H., 2018. Mutagenic primer-based PCR-RFLP assay for genotyping IRGM gene promoter variant rs4958843 (C/T). Journal of Clinical Laboratory Analysis, 32(4), p.e22346. doi: 10.1002/jcla.22346. Epu… [cited by applicant]
Zhu, D., Wang, J., Yang, D., Xi, J. and Li, J., 2021. High-throughput profiling of Cas12a orthologues and engineered variants for enhanced genome editing activity. International Journal of Molecular Sciences, 22(24), p.… [cited by applicant]
Wang, X., Yang, T., Zhang, Y., Zeng, Z., Wei, Q., Chen, P., Yang, S., Huang, Y., Zhang, Y., Lu, H. and Wu, L., 2024. Optimization and Clinical Application Potential of Single Nucleotide Polymorphism Detection Method Bas… [cited by applicant]